Johannes M. Waldschmidt

<scp>CXCL</scp>12 and <scp>CXCR</scp>7 are relevant targets to reverse cell adhesion‐mediated drug resistance in multiple myeloma

Johannes M. Waldschmidt, Anna Simon, Dagmar Wider et al. · British Journal of Haematology · 2017 · 79 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Dynamic transcriptional reprogramming leads to immunotherapeutic vulnerabilities in myeloma

Julia Frede, Praveen Anand, Noori Sotudeh et al. · Nature Cell Biology · 2021 · 54 citations · Full text

Life Sciences, Immunology, Molecular Biology +12

Large registry analysis to accurately define second malignancy rates and risks in a well-characterized cohort of 744 consecutive multiple myeloma patients followed-up for 25 years

Monika Engelhardt, Gabriele Ihorst, Ola Landgren et al. · Haematologica · 2015 · 53 citations · Full text

Medicine, Hematology, Oncology +16

Spatial transcriptomics reveals profound subclonal heterogeneity and T-cell dysfunction in extramedullary myeloma

Mara John, Moutaz Helal, Johannes Duell et al. · Blood · 2024 · 53 citations

Life Sciences, Hematology, Oncology +12

Potent <i>in vitro</i> and <i>in vivo</i> activity of sorafenib in multiple myeloma: induction of cell death, <scp>CD</scp>138‐downregulation and inhibition of migration through actin depolymerization

Josefina Udi, Julia Schüler, Dagmar Wider et al. · British Journal of Haematology · 2013 · 42 citations

Medicine, Oncology, Pharmacology +15